The company remains entirely pre-revenue, with zero recorded sales over the last ten quarters and quarterly operating losses consistently ranging between $1.3 million and $4.3 million.
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6.17K | 351.62K | 515.58K | 1.41M | 559.36K |
| Revenue Growth % | - | - | - | - | - | - | - | -100% | -98.24% | -31.8% | -63.44% | 152.09% | - |
| Cost of Goods Sold | 39.72K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 172.78K | 235.88K | 666.23K | 259.14K |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | 49.14% | 45.75% | 47.25% | 46.33% |
| Gross Profit | -39.72K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6.17K | 178.84K | 279.7K | 743.83K | 300.21K |
| Gross Margin % | - | - | - | - | - | - | - | - | 100% | 50.86% | 54.25% | 52.75% | 53.67% |
| Gross Profit Growth % | - | - | - | - | - | - | - | -100% | -96.55% | -36.06% | -62.4% | 147.77% | - |
| Operating Expenses | 6.43M | 5.76M | 10.82M | 10.52M | 13.16M | 11.5M | 11.5M | 10.84M | 9.03M | 4.8M | 2.07M | 2.31M | 1.83M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | 146180.47% | 1366.5% | 401.77% | 163.99% | 326.52% |
| Selling, General & Admin | 4.37M | 3.91M | 7.63M | 5.52M | 6.6M | 6.02M | 5.58M | 4.27M | 4.02M | 2.87M | 1.58M | 1.27M | 953.22K |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | 65033.62% | 817.3% | 305.69% | 90.32% | 170.41% |
| Research & Development | 2.1M | 1.85M | 3.19M | 5M | 6.55M | 5.48M | 5.92M | 6.57M | 4.72M | 1.93M | 495.38K | 1.04M | 873.17K |
| R&D % of Revenue | - | - | - | - | - | - | - | - | 76489.55% | 549.19% | 96.08% | 73.68% | 156.1% |
| Other Operating Expenses | -39.72K | 0 | 0 | 0 | 0 | 0 | 8.84K | -106.9K | 287.54K | 0 | 0 | 0 | 0 |
| Operating Income | -6.47M | -5.76M | -10.82M | -10.52M | -13.16M | -11.5M | -11.5M | -10.84M | -9.02M | -4.63M | -1.79M | -1.57M | -1.53M |
| Operating Margin % | - | - | - | - | - | - | - | - | -146080.47% | -1315.63% | -347.52% | -111.24% | -272.85% |
| Operating Income Growth % | - | 46.72% | -2.82% | 20.04% | -14.43% | 0.03% | -6.07% | -20.23% | -94.96% | -158.19% | -14.23% | -2.78% | - |
| EBITDA | -6.32M | -5.61M | -10.61M | -10.25M | -12.92M | -11.27M | -11.34M | -10.73M | -8.95M | -4.56M | -1.73M | -1.5M | -1.49M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | -144973.96% | -1298.15% | -334.93% | -106.12% | -266.19% |
| EBITDA Growth % | 32.16% | 47.17% | -3.57% | 20.72% | -14.63% | 0.55% | -5.67% | -19.86% | -96.09% | -164.33% | -15.4% | -0.5% | - |
| D&A (Non-Cash Add-back) | 151.43K | 157.29K | 206.17K | 275.45K | 234.26K | 224.41K | 165.25K | 115.01K | 68.32K | 61.48K | 64.94K | 72.22K | 37.24K |
| EBIT | -6.47M | -5.76M | -10.82M | -10.52M | -13.16M | -11.5M | -11.49M | -10.95M | -9.07M | -4.63M | -1.79M | -1.57M | -1.53M |
| Net Interest Income | 0 | 0 | 0 | 0 | -21.53K | 0 | -232.19K | -2.35M | -729.24K | 0 | 0 | 0 | 0 |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 232 | 2.35K | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 21.53K | 0 | 232.43K | 2.36M | 729.24K | 0 | 0 | 0 | 0 |
| Other Income/Expense | -834.95K | -1.26M | -690.8K | 460.49K | -21.53K | 267.06K | -223.58K | -2.46M | -777.25K | -750.9K | -983.61K | -710.63K | -654.7K |
| Pretax Income | -7.3M | -7.03M | -11.51M | -10.06M | -13.18M | -11.23M | -11.73M | -13.31M | -9.8M | -5.38M | -2.78M | -2.28M | -2.18M |
| Pretax Margin % | - | - | - | - | - | - | - | - | -158669.6% | -1529.19% | -538.3% | -161.64% | -389.89% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -7.3M | -7.03M | -11.51M | -10.06M | -13.18M | -11.23M | -11.73M | -13.31M | -9.8M | -5.38M | -2.78M | -2.28M | -2.18M |
| Net Margin % | - | - | - | - | - | - | - | - | -158669.6% | -1529.19% | -538.3% | -161.64% | -389.89% |
| Net Income Growth % | 25.24% | 38.93% | -14.39% | 23.67% | -17.34% | 4.22% | 11.88% | -35.83% | -82.19% | -93.74% | -21.77% | -4.51% | - |
| Net Income (Continuing) | -7.3M | -7.03M | -11.51M | -10.06M | -13.18M | -11.23M | -11.73M | -13.31M | -9.8M | -5.38M | -2.78M | -2.28M | -2.18M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -6.09 | -8.93 | -10.25 | -5.89 | -6.84 | -5.47 | -12.47 | -41.48 | -43.49 | -27.47 | -14.21 | -11.67 | -71.20 |
| EPS Growth % | 37.23% | 12.88% | -74.02% | 13.89% | -25.05% | 56.13% | 69.94% | 4.62% | -58.32% | -93.31% | -21.77% | 83.61% | - |
| EPS (Basic) | - | -8.93 | -10.25 | -5.89 | -4.57 | -5.47 | -12.47 | -41.48 | -43.49 | -27.47 | -14.21 | -11.67 | -72.70 |
| Diluted Shares Outstanding | 1.2M | 787.02K | 1.12M | 1.71M | 1.93M | 2.05M | 959.61K | 375K | 225.24K | 195.75K | 195.35K | 195.35K | 30.63K |
| Basic Shares Outstanding | 1.2M | 787.02K | 1.12M | 1.71M | 1.93M | 2.05M | 959.61K | 375K | 225.24K | 195.75K | 195.35K | 195.35K | 30K |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - | - |
Imminent liquidity and dilution risk
As indicated by the company's historical financial statements, ENDRA Life Sciences remains entirely pre-revenue, with zero recorded sales across the last ten quarters, underscoring the significant execution gap between its proprietary TAEUS platform development and the achievement of a sustainable, market-validated commercial revenue stream for the firm.
The lack of top-line growth highlights the company's status as a purely developmental entity rather than a commercial-stage medical device firm. Investors should monitor whether the transition from R&D to market entry can be achieved before the current capital runway is fully exhausted.
According to recent SEC filings, the company's operating expenses remain heavily skewed toward R&D and SG&A, with quarterly operating losses consistently ranging between $1.3 million and $4.3 million, reflecting a high-burn cost structure that lacks any offsetting gross margin contribution from product sales or service revenue.
The persistent operating losses suggest that the company is currently unable to achieve operational self-sufficiency. The reliance on external funding to cover these non-discretionary expenses implies that the cost structure is currently decoupled from any near-term revenue generation potential.
Based on reported figures, the company's EPS volatility is heavily influenced by frequent capital raises and stock-based compensation, which totaled $574.5K in 2026Q1 alone, masking the underlying operational performance and complicating the assessment of true shareholder value creation in this pre-revenue, high-burn environment.
The frequent use of equity-linked financing instruments suggests that the reported net losses may not fully capture the economic cost of capital to existing shareholders. Analysts should focus on the fully diluted share count to better understand the impact of ongoing financing activities on per-share metrics.
As reported in financial statements, the company's cash reserves have dwindled to approximately $762,365, a critical level that suggests an imminent requirement for further dilutive financing or a potential going concern qualification, which may severely impair the equity value for current shareholders in the near term.
The current cash position appears insufficient to support the ongoing R&D and regulatory requirements necessary for the TAEUS platform's commercialization. This liquidity shortfall warrants extreme caution, as the company's survival is increasingly contingent upon its ability to secure capital in a challenging market for micro-cap diagnostics.
Quick answers to the most common questions about buying NDRA stock.
For fiscal year 2025, ENDRA Life Sciences Inc. (NDRA) reported total revenue of $0.0M. This represents a 100.0% decline compared to $0.6M in 2014.
ENDRA Life Sciences Inc. (NDRA) reported a net loss of $7.0M for the fiscal year ending 2025.